Qualcomm Announces Agreement with LifeScan Inc., a Johnson & Johnson Diabetes Care Company, to Inform Patient Care with Connected Blood Glucose Meters

Qualcomm Incorporated (NASDAQ: QCOM), through its subsidiary Qualcomm Life, Inc., announced today its agreement with LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC), to streamline wireless data capture from LifeScan's OneTouch Verio Flex® blood glucose meters to physicians to enable more informed care. Qualcomm Life's medical-grade 2net™ solution will power the connectivity for efficient, cable-free data collection.

By using Qualcomm Life's medical-grade 2net™ solution, physicians will be able to conveniently access all of the patients' blood glucose data from Lifescan's OneTouch Verio Flex® blood glucose monitoring system with built-in Bluetooth® Smart Technology, which wirelessly sends data to the OneTouch Reveal® cloud-based application. Prior to leveraging Qualcomm Life's 2net solution, the data capture process was manual and cumbersome for physicians, requiring multiple cables and software versions. This new connected diabetes care provides streamlined access to a patient's historical and recent blood glucose levels, empowering physicians and the care team to make more proactive, informed care decisions based on data trends.

The companies plan to deploy the 2net solution to select physician offices in the Fall of 2017, and expand globally in 2018.

"Enabling timely access to blood glucose data generates actionable insights for physicians and patients for more informed diabetes care management," said Rick Valencia, president, Qualcomm Life. "The secure, wireless data capture that 2net provides is valuable for clinicians as they seek transformative ways to treat people with diabetes efficiently and effectively across the care continuum."   

About Qualcomm

Qualcomm's technologies powered the smartphone revolution and connected billions of people. We pioneered 3G and 4G – and now we are leading the way to 5G and a new era of intelligent, connected devices. Our products are revolutionizing industries, including automotive, computing, IoT, healthcare and data center, and are allowing millions of devices to connect with each other in ways never before imagined. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, our QCT semiconductor business. For more information, visit Qualcomm's website, OnQ blog, Twitter and Facebook pages.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.